Upstream Bio (NASDAQ:UPB) Stock Rating Lowered by Wall Street Zen

Upstream Bio (NASDAQ:UPB) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Several other brokerages have also issued reports on UPB. Evercore lowered shares of Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 target price for the company. in a research report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Upstream Bio in a report on Wednesday, January 21st. Mizuho upgraded shares of Upstream Bio to a “strong-buy” rating in a research report on Thursday, December 18th. Finally, Lifesci Capital initiated coverage on Upstream Bio in a research note on Tuesday, December 2nd. They issued an “outperform” rating and a $43.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $39.00.

Upstream Bio Price Performance

Shares of NASDAQ UPB opened at $8.67 on Friday. The stock’s 50-day simple moving average is $15.93 and its two-hundred day simple moving average is $21.40. Upstream Bio has a twelve month low of $5.14 and a twelve month high of $33.68. The firm has a market capitalization of $471.82 million, a P/E ratio of -3.25 and a beta of 3.00.

Upstream Bio (NASDAQ:UPB) last issued its quarterly earnings results on Thursday, March 26th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.06). Upstream Bio had a negative net margin of 5,026.03% and a negative return on equity of 36.48%. The business had revenue of $0.67 million for the quarter, compared to the consensus estimate of $0.52 million. As a group, research analysts anticipate that Upstream Bio will post -4.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of UPB. Bain Capital Life Sciences Investors LLC raised its holdings in Upstream Bio by 6.3% during the 2nd quarter. Bain Capital Life Sciences Investors LLC now owns 2,439,538 shares of the company’s stock valued at $26,786,000 after buying an additional 144,216 shares during the last quarter. Integral Health Asset Management LLC bought a new stake in Upstream Bio in the 3rd quarter worth $10,816,000. Geode Capital Management LLC grew its holdings in Upstream Bio by 57.5% in the 2nd quarter. Geode Capital Management LLC now owns 646,635 shares of the company’s stock worth $7,101,000 after acquiring an additional 235,958 shares during the last quarter. Norges Bank purchased a new position in shares of Upstream Bio in the second quarter valued at about $10,650,000. Finally, Virtus Investment Advisers LLC purchased a new position in shares of Upstream Bio in the second quarter valued at about $89,000.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.